Peeling Skin SyndromeNCT06749561
A Comparative Investigation of Efficacy and Complications in Light and Deep Chemical Peels
An observational study of Peeling Skin Syndrome, run by Superior University at 1 site in Pakistan.
Trial summary
Chemical peeling involves applying substances to the skin to induce controlled damage, which promotes the regeneration of fresh skin cells and enhances the skin's appearance. Read more about this study
- Who is it for?
- Ages 18 to 35 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Peeling Skin Syndrome
- What is being tested?
- Group 1
- How many people
- 112 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Feb 2024to 1 Mar 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: To check the outcomes of Efficacy and Complications in Light and Deep Chemical Peels
Who may be able to join
- Healthy males and females aged 18-35 years.
- Willing to provide informed consent and follow the treatment protocol.
Who cannot join
- Pregnant or breastfeeding women.
- Active skin conditions (e.g., acne, eczema).
- Use of medications that affect skin healing.
- Known allergies to chemical peel substances.
Trial locations and contacts
1 site in 1 country.
About this study
Chemical peeling involves applying substances to the skin to induce controlled damage, which promotes the regeneration of fresh skin cells and enhances the skin's appearance.
Read the detailed description
This study will be a cross-sectional analysis with a sample size of 112 patients.
- Conditions
- Peeling Skin Syndrome
- Being tested
- Group 1
- Medical subject headings
- Peeling Skin Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group 1Diagnostic test
To Compare the safety and effectiveness of boyh types
What is being measured
The primary outcome is the main question the study is designed to answer.
Dermatological Assessment Score (DAS)
The area-wise percentage involvement of the involved sites is calculated as: 1 = less than 10% area; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; and 6 = more than 90%. The maximum score of PASI is 72. PASI 75 is a 75% reduction of baseline PASI score.
Measured: 12 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Dec 2024
- Study start1 Feb 2024
- Primary completion1 Aug 2024
- Study completion1 Mar 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peeling Skin SyndromeStudies of the same condition, open and under way.
- More trials run by Superior UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 112 participants (actual)
Sponsor and investigators
- Lead sponsor
- Superior University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Muhammad Naveed Babur, Superior University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06749561
- Sponsor's protocol ID
- MSAHS/Batch-Spring23/057
- Status last verified
- Dec 2024
- First submitted
- 19 Dec 2024
- Last updated
- 27 Dec 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparative Investigation of Efficacy and Complications in Light and Deep Chemical Peels
- ClinicalTrials.gov ID
- NCT06749561
- Acronym / sponsor ID
- MSAHS/Batch-Spring23/057
- Conditions
- Peeling Skin Syndrome
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 112 participants (actual)
- Lead sponsor
- Superior UniversityUniversity, hospital or other
- Study start
- 1 Feb 2024 (actual)
- Primary completion
- 1 Aug 2024 (actual)
- Study completion
- 1 Mar 2025 (estimated)
- First posted
- 27 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chemical peeling involves applying substances to the skin to induce controlled damage, which promotes the regeneration of fresh skin cells and enhances the skin's appearance.
Detailed description
This study will be a cross-sectional analysis with a sample size of 112 patients.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- To check the outcomes of Efficacy and Complications in Light and Deep Chemical Peels
Key inclusion criteria (2 listed)
- Healthy males and females aged 18-35 years.
- Willing to provide informed consent and follow the treatment protocol.
Key exclusion criteria (4 listed)
- Pregnant or breastfeeding women.
- Active skin conditions (e.g., acne, eczema).
- Use of medications that affect skin healing.
- Known allergies to chemical peel substances.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group 1To Compare the safety and effectiveness of boyh types | Diagnostic test | – |
Primary outcome
Dermatological Assessment Score (DAS)
Time frame: 12 Months
The area-wise percentage involvement of the involved sites is calculated as: 1 = less than 10% area; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; and 6 = more than 90%. The maximum score of PASI is 72. PASI 75 is a 75% reduction of baseline PASI score.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Dec 2024.
- Individual participant dataSharing planned: No
Related trials for Peeling Skin Syndrome
Not yet recruitingEarly Phase 1
Traditional Chinese Medicine Treatment for Capecitabine-Related Hand-Foot Syndrome
Palmar and Plantar Erythema, Numbness of the Four Limbs
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Peeling Skin Syndrome, run by Superior University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 27 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dermatological Assessment Score (DAS) (time frame: 12 Months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Dec 2024.